Research
Hormonal
The FDA has approved GLP-1R agonists, liraglutide and semaglutide, for the management of obesity.
Practitioners can consider GLP-1R agonists as viable pharmacological options for obesity management.
StrongSupportsmedium confidence
However, with FDA approval of the glucagon-like peptide 1 receptor (GLP-1R) agonists, liraglutide and semaglutide, for the management of obesity, it is hoped the tide is beginning to turn.
Why this rating
The claim is based on regulatory approval, indicating a high level of evidence.
Source
Is polypharmacy the future for pharmacological management of obesity?
Ryan A. Lafferty et al. · Current Opinion in Endocrine and Metabolic Research · 2022
DOI 10.1016/j.coemr.2022.100322
reviewCited 8×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →